Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The microenvironment of pancreatic ductal adenocarcinoma (PDAC) with extensive desmoplastic stroma contributes to aggressive cancer behavior. Angiotensin system inhibitors (ASIs) reduce stromal fibrosis and are a promising therapeutic strategy. The purpose of this study was to examine how ASIs affected the oncological results of patients who had their PDAC removed. Materials and Methods: A retrospective assessment was conducted on the clinicopathological and survival data of patients who received curative resection for PDAC at Severance Hospital between January 2012 and December 2019. Results: A total of 410 participants (228 male and 182 female), with a median follow-up period of 12.8 months, were included in this study. Patients were divided into three groups, based on ASI use and history of hypertension: group 1, normotensive and never used ASI (n=210, 51.2%); group 2, ASI non-users with hypertension (n=50, 12.2%); and group 3, ASI users with hypertension (n=150, 36.6%). The three groups did not differ significantly in terms of age, sex, kind of operation, T and N stages, or adjuvant and neoadjuvant therapy. Moreover, there was no discernible difference in disease-free survival between those who used ASI and those who did not (p=0.636). The 5-year overall survival (OS) rates in groups 1, 2, and 3 were 52.6%, 32.3%, and 38.0%, respectively. However, the OS rate of ASI users was remarkably higher than that of non-users (p=0.016). Conclusion: In patients with resected PDAC, ASI is linked to longer survival rates. Furthermore, for individuals with hypertension, ASI in conjunction with conventional chemotherapy may be an easy and successful treatment option.
Abstract
Purpose: The microenvironment of pancreatic ductal adenocarcinoma (PDAC) with extensive desmoplastic stroma contributes to aggressive cancer behavior. Angiotensin system inhibitors (ASIs) reduce stromal fibrosis and are a promising therapeutic strategy. The purpose of this study was to examine how ASIs affected the oncological results of patients who had their PDAC removed. Materials and Methods: A retrospective assessment was conducted on the clinicopathological and survival data of patients who received curative resection for PDAC at Severance Hospital between January 2012 and December 2019. Results: A total of 410 participants (228 male and 182 female), with a median follow-up period of 12.8 months, were included in this study. Patients were divided into three groups, based on ASI use and history of hypertension: group 1, normotensive and never used ASI (n=210, 51.2%); group 2, ASI non-users with hypertension (n=50, 12.2%); and group 3, ASI users with hypertension (n=150, 36.6%). The three groups did not differ significantly in terms of age, sex, kind of operation, T and N stages, or adjuvant and neoadjuvant therapy. Moreover, there was no discernible difference in disease-free survival between those who used ASI and those who did not (p=0.636). The 5-year overall survival (OS) rates in groups 1, 2, and 3 were 52.6%, 32.3%, and 38.0%, respectively. However, the OS rate of ASI users was remarkably higher than that of non-users (p=0.016). Conclusion: In patients with resected PDAC, ASI is linked to longer survival rates. Furthermore, for individuals with hypertension, ASI in conjunction with conventional chemotherapy may be an easy and successful treatment option.
참고문헌 (32)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- McGuigan A, "Pancreatic cancer : a review of clinical diagnosis, epidemiology, treatment and outcomes", World J Gastroenterol, 24, pp.4846~4861 (2018)
- Garcea G, "Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature", JOP, 9, pp.99~132 (2008)
- Neoptolemos JP, "Therapeutic developments in pancreatic cancer : current and future perspectives", Nat Rev Gastroenterol Hepatol, 15, pp.333~348 (2018)
- Versteijne E, "Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer", Br J Surg, 105, pp.946~958 (2018)
- Rajappa SJ, "Neoadjuvant therapy for pancreas cancer : global perspective and optimal care pathways in low to middle-income countries", J Surg Oncol, 123, pp.1441~1448 (2021)
- Kleeff J, "Pancreatic cancer", Nat Rev Dis Primers, 2, pp.16022~ (2016)
- Dougan SK, "The pancreatic cancer microenvironment", Cancer J, 23, pp.321~325 (2017)
- Orth M, "Pancreatic ductal adenocarcinoma : biological hallmarks, current status, and future perspectives of combined modality treatment approaches", Radiat Oncol, 14, pp.141~ (2019)
- Brahmer JR, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", N Engl J Med, 366, pp.2455~2465 (2012)
- Diop-Frimpong B, "Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors", Proc Natl Acad Sci U S A, 108, pp.2909~2914 (2011)
- Tan DC, "Therapeutic targeting of cancer stem cells in human glioblastoma by manipulating the renin-angiotensin system", Cells, 8, pp.1364~ (2019)
- Rachow T, "Risk of lung cancer and renin-angiotensin blockade : a concise review", J Cancer Res Clin Oncol, 147, pp.195~204 (2021)
- Chauhan VP, "Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels", Nat Commun, 4, pp.2516~ (2013)
- George AJ, "The renin-angiotensin system and cancer : old dog, new tricks", Nat Rev Cancer, 10, pp.745~759 (2010)
- Pinter M, "Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy", Sci Transl Med, 9, pp.eaan5616~ (2017)
- Liu H, "Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma", Clin Cancer Res, 23, pp.5959~5969 (2017)
- Murphy JE, "Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer : a phase 2 clinical trial", JAMA Oncol, 5, pp.1020~1027 (2019)
- Uesaka K, "Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial(JASPAC 01)", Lancet, 388, pp.248~257 (2016)
- Oettle H, "Adjuvant chemotherapy with gemcitabine and longterm outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial", JAMA, 310, pp.1473~1481 (2013)
- Sinn M, "CONKO-005 : adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer : a multicenter randomized phase III trial", J Clin Oncol, 35, pp.3330~3337 (2017)
- Shaib Y, "The impact of curative intent surgery on the survival of pancreatic cancer patients : a U. S. population-based study", Am J Gastroenterol, 102, pp.1377~1382 (2007)
- Keizman D, "Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma : a retrospective examination", Eur J Cancer, 47, pp.1955~1961 (2011)
- Nakai Y, "Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine", Br J Cancer, 103, pp.1644~1648 (2010)
- Wilop S, "Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy", J Cancer Res Clin Oncol, 135, pp.1429~1435 (2009)
- Chae YK, "Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and", or statins, 2011, pp.29, 585~593
- Kumar V, "Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma", Transl Oncol, 9, pp.431~437 (2016)
- Mandilaras V, "The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer", Br J Cancer, 116, pp.103~108 (2017)
- Jiang W, "The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer : a systematic review and meta-analysis", Expert Rev Gastroenterol Hepatol, 16, pp.547~553 (2022)
- Keith SW, "Angiotensin blockade therapy and survival in pancreatic cancer : a population study", BMC Cancer, 22, pp.150~ (2022)
- Liu H, "The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients", HPB(Oxford), 25, pp.320~329 (2023)
- Tajaldini M, "Strategy of targeting the tumor microenvironment via inhibition of fibroblast", fibrosis remodeling new era to cancer chemoimmunotherapy resistance, 2023, pp.957, 175991~